YAP1 基因敲除对胰腺癌L3.6细胞增殖及迁移能力的影响

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1868 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的：研究胰腺癌细胞中YAP1对胰腺癌细胞增殖和迁移能力的影响。方法：利用CRISPR-Cas9技术，在人胰腺癌L3.6细胞中敲除YAP1 基因，并用Western blot验证；通过MTT比色法及EdU流式检测敲除YAP1 前后的癌细胞增殖能力；用细胞划痕及Transwell实验研究迁移能力。结果：成功获得YAP1 敲除的L3.6 稳定细胞株（YAP1 -KO）。相对于野生型的L3.6细胞，YAP1 -KO细胞的增殖与生长能力明显下降，细胞迁移能力也明显减弱。结论：YAP1 基因敲除显著降低胰腺癌L3.6细胞的增殖和迁移能力，可能为靶向治疗胰腺癌提供新的潜在靶标。

	服务
	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	陈千杰
	张金三
	郭强
	董晶莱
	郭丽莎
	李校堃

关键词 ： Yes-关联蛋白1, 人胰腺癌细胞, Cas9技术, 增殖, 迁移

Abstract：Objective: To investigate the effects of YAP1 on proliferation and migration in pancreatic cancer cells. Methods: CRISPR-Cas9 technique was used to knockout the YAP1 gene in human pancreatic cancer L3.6 cells, and Western blot was used to verify it. The proliferation ability of L3.6 cells before and after YAP1 knockout was detected by MTT colorimetry and EdU flow cytometry. The migration ability was measured by cells scratch and Transwell assay. Results: The L3.6 stable cell lines of YAP1 knockout (YAP1-KO) were successfully obtained. Compared with wild type L3.6 cell lines, the proliferation and growth abilities of YAP1-KO cells were significantly decreased, and the invasion ability of cells was also decreased. Conclusion: Knockout of YAP1 gene can significantly reduce the proliferation and migration abilities of pancreatic cancer L3.6 cells, which might provide a new potential target for targeted therapy of pancreatic cancer.

Key words： Yes-associate protein 1 human pancreatic cancer cells Cas9 technology proliferation migration

收稿日期: 2018-01-15

基金资助:国家自然科学基金青年基金资助项目（81702912）。

通讯作者: 李校堃，教授，Email：xiaokunli@wmu.edu.cn。

作者简介: 陈千杰（1992-），男，浙江温州人，硕士生。

链接本文:

https://xb.wmu.edu.cn/CN/ 或 https://xb.wmu.edu.cn/CN/Y2018/V48/I6/391

[1] PHUA L C, GOH S, TAI D W M, et al. Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabine[J]. Cancer Chemother Pharmacol, 2018, 81(2): 277-289.
[2] YUAN Y, LI D, LI H, et al. YAP overexpression promotes the epithelial-mesenchymal transition and chemoresistance in pancreatic cancer cells[J]. Mol Med Rep, 2016, 13(1): 237-242.
[3] ZHANG H, VON GISE A, LIU Q, et al. Yap1 is required for endothelial to mesenchymal transition of the atrioventricular cushion[J]. J Biol Chem, 2014, 289(27): 18681-18692.
[4] ZHANG Q, ZHANG Y, PARSELS J D, et al. Fbxw7 deletion accelerates kras(G12D)-driven pancreatic tumorigenesis via yap accumulation[J]. Neoplasia, 2016, 18(11): 666-673.
[5] 史梦婕, 邵松军, 李洁媚, 等. Hippo通路与肿瘤相关性研究进展[J]. 中国细胞生物学学报, 2014, 36(3): 361-365.
[6] DIEPENBRUCK M, WALDMEIER L, IVANEK R, et al. Tead2 expression levels control the subcellular distribution of Yap and Taz, zyxin expression and epithelial-mesenchymal transition[J]. J Cell Sci, 2014, 127(Pt 7): 1523-1536.
[7] PEI T, LI Y, WANG J, et al. YAP is a critical oncogene in human cholangiocarcinoma[J]. Oncotarget, 2015, 6(19): 17206-17220.
[8] VLUG E J, VAN DE VEN R A, VERMEULEN J F, et al. Nuclear localization of the transcriptional coactivator YAP is associated with invasive lobular breast cancer[J]. Cell Oncol (Dordr), 2013, 36(5): 375-384.
[9] SHEN S, GUO X, YAN H, et al. A miR-130a-YAP positive feedback loop promotes organ size and tumorigenesis[J]. Cell Res, 2015, 25(9): 997-1012.
[10] WEI H, WANG F, WANG Y, et al. Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP-TEAD complex[J]. Cancer Sci, 2017, 108(3): 478-487.
[11] ZHANG Y, ZHOU M, WEI H, et al. Furin promotes epithelial-mesenchymal transition in pancreatic cancer cells via Hippo-YAP pathway[J]. Int J Oncol, 2017, 50(4): 1352-1362.
[12] ZHU Z M, XU Y F, SU Q J, et al. Prognostic significance of microRNA-141 expression and its tumor suppressor function in human pancreatic ductal adenocarcinoma[J]. Mol Cell Biochem, 2014, 388(1-2): 39-49.
[13] HAN D, BYUN S H, PARK S, et al. YAP/TAZ enhance mammalian embryonic neural stem cell characteristics in a Tead-dependent manner[J]. Biochem Biophys Res Commun, 2015, 458(1): 110-116.
[14] HIRATE YSASAKI H. The role of angiomotin phosphorylation in the Hippo pathway during preimplantation mouse de-velopment[J]. Tissue Barriers, 2014, 2(1): e28127.
[15] GRETEN F R. YAP1 takes over when oncogenic K-Ras slumbers[J]. Cell, 2014, 158(1): 11-12.
[16] KAPOOR A, YAO W, YING H, et al. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic can-cer[J]. Cell, 2014, 158(1): 185-197.
[17] 宋娟,叶小群. Hippo-YAP信号通路为靶点的肿瘤治疗研究进展[J]. 中国肿瘤临床, 2015(17): 876-880.
[18] HSU P D, SCOTT D A, WEINSTEIN J A, et al. DNA targeting specificity of RNA-guided Cas9 nucleases[J]. Nat Biotechnol, 2013, 31(9): 827-832.
[19] RAN F A, HSU P D, LIN C Y, et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity[J]. Cell, 2013, 154(6): 1380-1389.
[20] 周文媛, 任军, 纪元, 等. N-乙酰氨基半乳糖转移酶6对乳腺癌细胞MCF-7增殖和迁移的影响[J]. 温州医科大学学报, 2017, 47(12): 864-868, 874.
[21] 郑斌, 吴齐全, 周克文, 等. 转录因子SOX7对前列腺癌PC-3细胞生物学活性的影响及其机制[J]. 温州医科大学学报, 2017, 47(9): 678-682.
[22] ZHANG Q, CHEN X, ZHANG X, et al. Knockdown of TMEM14A expression by RNAi inhibits the proliferation and invasion of human ovarian cancer cells[J]. Biosci Rep, 2016, 36(1): e00298.
[23] CHIU K Y, WU C C, CHIA C H, et al. Inhibition of growth, migration and invasion of human bladder cancer cells by antrocin, a sesquiterpene lactone isolated from Antrodia cinnamomea, and its molecular mechanisms[J]. Cancer Lett, 2016, 373(2): 174-184.